Encorafenib capsules 75 mg/capsule, 90 capsules/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• New primary malignancies, both cutaneous and noncutaneous: may occur. Malignant tumors are monitored and dermatologically evaluated before, during, and after treatment discontinuation.
• Tumorigenesis in BRAF wild-type tumors: Use of BRAF inhibitors may increase cell proliferation.
• Bleeding: Serious bleeding events may occur.
• Uveitis: Perform regular eye assessments and check for any visual impairments.
• Prolonged QT interval: electrolytes are monitored before and during treatment. Correcting electrolyte abnormalities and controlling cardiac risk factors for prolonged QT intervals. When the QTc is 500 milliseconds or more, stop using LuciEncor.
• Embryo-fetal toxicity: May cause harm to the fetus. Women of childbearing potential are advised to be aware of the potential risks to the fetus and to use effective non-hormonal methods of contraception.

Medication risks

Adverse Reactions
The most common adverse effects (> 25%) of LuciEncor in combination with binimetinib are fatigue, nausea, vomiting, abdominal pain, and joint pain.